Background: Acute kidney injury (AKI) is a major comorbidity in hospitalised patients. Patients with severe AKI require continuous renal replacement therapy (CRRT) when they are haemodynamically unstable. CRRT is prescribed assuming it is delivered over 24 hours. However, it is interrupted when the extracorporeal circuits clot and the replacement is required. The interruption may impair the solute clearance as it causes under dosing of CRRT. To prevent the circuit clotting, anticoagulation drugs are frequently used.

Objectives: To assess the benefits and harms of pharmacological interventions for preventing clotting in the extracorporeal circuits during CRRT.

Search Methods: We searched the Cochrane Kidney and Transplant Register of Studies up to 12 September 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.

Selection Criteria: We selected randomised controlled trials (RCTs or cluster RCTs) and quasi-RCTs of pharmacological interventions to prevent clotting of extracorporeal circuits during CRRT.

Data Collection And Analysis: Data were abstracted and assessed independently by two authors. Dichotomous outcomes were calculated as risk ratio (RR) with 95% confidence intervals (CI). The primary review outcomes were major bleeding, successful prevention of clotting (no need of circuit change in the first 24 hours for any reason), and death. Evidence certainty was determined using the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach.

Main Results: A total of 34 completed studies (1960 participants) were included in this review. We identified seven ongoing studies which we plan to assess in a future update of this review. No included studies were free from risk of bias. We rated 30 studies for performance bias and detection bias as high risk of bias. We rated 18 studies for random sequence generation,ààsix studies for the allocation concealment, three studies for performance bias, three studies for detection bias,à nine studies for attrition bias,à14 studies for selective reporting and nine studies for the other potential source of bias, as having low risk of bias. We identified eight studies (581 participants) that compared citrate with unfractionated heparin (UFH). Compared to UFH, citrate probably reduces major bleeding (RR 0.22, 95% CI 0.08 to 0.62; moderate certainty evidence) and probably increases successful prevention of clotting (RR 1.44, 95% CI 1.10 to 1.87; moderate certainty evidence). Citrate may have little or no effect on death at 28 days (RR 1.06, 95% CI 0.86 to 1.30, moderate certainty evidence). Citrate versus UFH may reduce the number of participants who drop out of treatment due to adverse events (RR 0.47, 95% CI 0.15 to 1.49; low certainty evidence). Compared to UFH, citrate may make little or no difference to the recovery of kidney function (RR 1.04, 95% CI 0.89 to 1.21; low certainty evidence). Compared to UFH, citrate may reduceàthrombocytopenia (RR 0.39, 95% CI 0.14 to 1.03; low certainty evidence). It was uncertain whether citrate reduces a cost to health care services because of inadequate data. For low molecular weight heparin (LMWH) versus UFH, six studies (250 participants) were identified. Compared to LMWH, UFH may reduce major bleeding (0.58, 95% CI 0.13 to 2.58; low certainty evidence). It is uncertain whether UFH versus LMWH reduces death at 28 days or leads to successful prevention of clotting. Compared to LMWH, UFH may reduce the number of patient dropouts from adverse events (RR 0.29, 95% CI 0.02 to 3.53; low certainty evidence). It was uncertain whether UFH versus LMWH leads to the recovery of kidney function because no included studies reported this outcome. It was uncertain whether UFH versus LMWH leads to thrombocytopenia. It was uncertain whether UFH reduces a cost to health care services because of inadequate data. For the comparison of UFH to no anticoagulation, one study (10 participants) was identified. It is uncertain whether UFH compare to no anticoagulation leads to more major bleeding. It is uncertain whether UFH improves successful prevention of clotting in the first 24 hours, death at 28 days, the number of patient dropouts due to adverse events, recovery of kidney function, thrombocytopenia, or cost to health care services because no study reported these outcomes. For the comparison ofàcitrate to no anticoagulation,àno completed study was identified.

Authors' Conclusions: Currently,àavailable evidence does not support the overall superiority of any anticoagulant to another. Compared to UFH, citrate probably reduces major bleeding and prevents clotting and probably has little or no effect on death at 28 days. For other pharmacological anticoagulation methods, there is no available data showing overall superiority to citrate or no pharmacological anticoagulation. Further studies are needed to identify patient populations in which CRRT should commence with no pharmacological anticoagulation or with citrate.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812343PMC
http://dx.doi.org/10.1002/14651858.CD012467.pub3DOI Listing

Publication Analysis

Top Keywords

certainty evidence
32
uncertain ufh
24
major bleeding
20
low certainty
20
studies
17
extracorporeal circuits
16
successful prevention
16
prevention clotting
16
ufh
16
compared ufh
16

Similar Publications

Background: There is substantial epidemiological evidence demonstrating that influenza contributes to cardiovascular events in patients who already have cardiovascular diseases. However, it is unclear the extent to which influenza vaccination influences the prognosis of patients with ischemic heart disease (IHD).

Methods: We conducted a search for eligible randomized controlled trials (RCTs) in PubMed, Cochrane, and Embase on March 11, 2024, to investigate the effect of the influenza vaccine on the prognosis of patients with IHD.

View Article and Find Full Text PDF

Background: The increasing number of studies of immersive virtual reality (VR) interventions for mental disorders call for an examination of the current level of evidence on their effectiveness. The findings may guide scalability and contribute to the advancement and optimization of immersive VR-based interventions for mental disorders.

Methods: A systematic literature search across four databases screened 2443 studies.

View Article and Find Full Text PDF

The effects of foot core exercises and minimalist footwear on foot muscle sizes, foot strength, and biomechanics: A systematic review and meta-analysis.

Clin Biomech (Bristol)

December 2024

Department of Rehabilitation Sciences, Musculoskeletal Rehabilitation Research Group, Katholieke Universiteit Leuven (KU Leuven), Bruges, Belgium; Universitaire Ziekenhuizen KU Leuven (UZ Leuven), Campus Pellenberg, Clinical Motion Analysis Laboratorium (CMAL), Lubbeek, Belgium; Haute Ecole Leonard De Vinci, Secteur Santé, Département de Podologie, Brussels, Belgium.

Background: Specific foot exercises and the use of minimalist shoes during running or daily life were suggested to strengthen the intrinsic foot muscles and to modify locomotion biomechanics. We aimed to review the effectiveness of these interventions to modify foot muscle sizes, foot strength, and biomechanical outcomes.

Method: PubMed, Embase, Cochrane Library and SportDiscus databases were searched (last update: 12 March 2024).

View Article and Find Full Text PDF

To optimize patient outcomes, healthcare decisions should be based on the most up-to-date high-quality evidence. Randomized controlled trials (RCTs) are vital for demonstrating the efficacy of interventions; however, information on how an intervention compares to already available treatments and/or fits into treatment algorithms is sometimes limited. Although different therapeutic classes are available for the treatment of chronic obstructive pulmonary disease (COPD), assessing the relative efficacy of these treatments is challenging.

View Article and Find Full Text PDF

Several meta-analyses have examined the effect of Nigella Sativa (N. Sativa) supplementation on inflammatory and oxidative markers, with conflicting results. So, the current study evaluated the effect of N.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!